Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods

Abstract In this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow n...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takeshi Yoroidaka, Kentaro Narita, Hiroyuki Takamatsu, Momoko Fujisawa, Shinji Nakao, Kosei Matsue
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/0183caa16ebe49ea857003f9cf702b0b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0183caa16ebe49ea857003f9cf702b0b
record_format	dspace
spelling	oai:doaj.org-article:0183caa16ebe49ea857003f9cf702b0b2021-12-02T14:49:11ZComparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods10.1038/s41598-021-89761-92045-2322https://doaj.org/article/0183caa16ebe49ea857003f9cf702b0b2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89761-9https://doaj.org/toc/2045-2322Abstract In this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow next-generation flow (NGF) method. A total of 96 samples derived from 69 patients with MM were assessed to determine the total cell acquisition number (tCAN), percentages of total and normal plasma cells (PCs), and MRD levels using two methods. We found that the tCAN was significantly higher with EuroFlow-NGF than with DuraClone (median 8.6 × 106 vs. 5.7 × 106; p < 0.0001). In addition, a significant correlation in the MRD levels between the two methods was noted (r = 0.92, p < 0.0001). However, in the qualitative analysis, 5.2% (5/96) of the samples showed discrepancies in the MRD levels. In conclusion, the DuraClone is a good option to evaluate MRD in multiple myeloma but it should be used with caution.Takeshi YoroidakaKentaro NaritaHiroyuki TakamatsuMomoko FujisawaShinji NakaoKosei MatsueNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Takeshi Yoroidaka Kentaro Narita Hiroyuki Takamatsu Momoko Fujisawa Shinji Nakao Kosei Matsue Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
description	Abstract In this study, the minimal residual disease (MRD) levels in patients with multiple myeloma (MM) were assessed by comparing the new 8-color single-tube multiparameter flow cytometry method (DuraClone), which reduces the cost of antibodies and labor burden of laboratories, with the EuroFlow next-generation flow (NGF) method. A total of 96 samples derived from 69 patients with MM were assessed to determine the total cell acquisition number (tCAN), percentages of total and normal plasma cells (PCs), and MRD levels using two methods. We found that the tCAN was significantly higher with EuroFlow-NGF than with DuraClone (median 8.6 × 106 vs. 5.7 × 106; p < 0.0001). In addition, a significant correlation in the MRD levels between the two methods was noted (r = 0.92, p < 0.0001). However, in the qualitative analysis, 5.2% (5/96) of the samples showed discrepancies in the MRD levels. In conclusion, the DuraClone is a good option to evaluate MRD in multiple myeloma but it should be used with caution.
format	article
author	Takeshi Yoroidaka Kentaro Narita Hiroyuki Takamatsu Momoko Fujisawa Shinji Nakao Kosei Matsue
author_facet	Takeshi Yoroidaka Kentaro Narita Hiroyuki Takamatsu Momoko Fujisawa Shinji Nakao Kosei Matsue
author_sort	Takeshi Yoroidaka
title	Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
title_short	Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
title_full	Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
title_fullStr	Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
title_full_unstemmed	Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods
title_sort	comparison of minimal residual disease detection in multiple myeloma between the duraclone and euroflow methods
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0183caa16ebe49ea857003f9cf702b0b
work_keys_str_mv	AT takeshiyoroidaka comparisonofminimalresidualdiseasedetectioninmultiplemyelomabetweentheduracloneandeuroflowmethods AT kentaronarita comparisonofminimalresidualdiseasedetectioninmultiplemyelomabetweentheduracloneandeuroflowmethods AT hiroyukitakamatsu comparisonofminimalresidualdiseasedetectioninmultiplemyelomabetweentheduracloneandeuroflowmethods AT momokofujisawa comparisonofminimalresidualdiseasedetectioninmultiplemyelomabetweentheduracloneandeuroflowmethods AT shinjinakao comparisonofminimalresidualdiseasedetectioninmultiplemyelomabetweentheduracloneandeuroflowmethods AT koseimatsue comparisonofminimalresidualdiseasedetectioninmultiplemyelomabetweentheduracloneandeuroflowmethods
_version_	1718389488434020352

Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods

Ejemplares similares